Social Media Ideas for Eli Lilly

<![CDATA[ Eli Lilly to Acquire Merida Biosciences for $2.8 Billion ]]>

<![CDATA[Eli Lilly Surpasses Wall Street Estimates on Injectable GLP-1 Drugs]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Reports Positive Results from Two Phase III Trials]]>

<![CDATA[Pharmaceutical Executive Daily: Eli Lilly Enters $2.8 Billion Agreement to Acquire Merida Biosciences]]>

<![CDATA[Eli Lilly to Acquire AtaiBeckley for $2.8 Billion ]]>

Eli Lilly Launches Attacks On Tirzepatide Generics

Eli Lilly and Co. fired off a round of lawsuits in Delaware federal court seeking to block generic versions of its tirzepatide weight loss and diabetes medications, targeting Sando...

<![CDATA[Pharmaceutical Executive Daily: Novo Nordisk Files Lawsuit Against Eli Lilly]]>

Eli Lilly inks $2.88B Merida buyout for autoimmune drugs against rogue antibodies

Eli Lilly has struck a deal to acquire Merida Biosciences for up to $2.875 billion, establishing a beachhead in efforts to treat disease through the selective degradation of pathog...

Eli Lilly tops new biopharma ranking on launch success, development speed

Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella’s inaugural Pipeline-to-Patient Productivity Index, which evaluated 25 la...

BofA points to the Eli Lilly market that could outsize the U.S.

Veeva Vault CRM Selected by Eli Lilly and Company

Veeva Systems announced that Eli Lilly and Company (Lilly) has committed to Veeva Vault CRM globally. Vault CRM is part of the Vault CRM Suite of applications that provides the tec...

Eli Lilly’s $100B incretin opportunity: Is more upside coming?

<![CDATA[Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly]]>

Eli Lilly’s pipeline in 2026: how the incretin boom is funding what comes next 

Take a look at the Eli Lilly pipeline in 2026 as the incretin franchise grows and fuels the rest of the company's pipeline. The post Eli Lilly’s pipeline in 2026: how the incretin...

<![CDATA[Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising, Alleging Misleading Dosing Comparisons]]>

Prediction: Here's What a $5,000 Investment in Eli Lilly Could Look Like in 5 Years

Eli Lilly's total return topped 367% over the past five years, largely thanks to enthusiasm for its GLP-1 offerings.

Lilly Claims 6 Vendors Illegally Sold Obesity Drug Candidate

Eli Lilly & Co. hit a medical spa business, compounding pharmacy and a group of chemical suppliers with claims they're illegally selling an obesity drug candidate Lilly is rese...

<![CDATA[Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb]]&...

Eli Lilly Just Announced a Major Acquisition. Here's What It Means.

The drug giant added to its immunotherapy portfolio.

Eli Lilly Debuts Advertisement Selling GLP-1s to Medicare Enrollees

Eli Lilly Debuts Advertisement Selling GLP-1s to Medicare Enrollees

Eli Lilly Debuts Advertisement Selling GLP-1s to Medicare Enrollees

Eli Lilly Debuts Advertisement Selling GLP-1s to Medicare Enrollees

Kirkland & Ellis Helps Eli Lilly Sue to Shut Down Alleged Black Market for GLP 1

Eli Lilly has filed six lawsuits, including five in Texas, against companies it says are illegally selling unapproved versions of its experimental weight-loss drug retatrutide amid...

Eli Lilly Has Been on an Acquisition Spree. How Much Could Its Latest Deals Boost the Stock?

The big story today with Eli Lilly is its hugely successful GLP-1 drugs, but the long-term story is likely to be about its acquisitions.

Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly’s GLP-1 Dru...